دورية أكاديمية
Effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with diabetic nephropathy
| العنوان: | Effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with diabetic nephropathy |
|---|---|
| المؤلفون: | Shengfu Jiao, MB, Yuxia Dong, MB, Xiang Chang, MB, Yanan Wu, MB, Haifeng Li, MB |
| المصدر: | Medicine, Vol 101, Iss 17, p e29080 (2022) |
| بيانات النشر: | Wolters Kluwer, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Medicine |
| مصطلحات موضوعية: | Medicine |
| الوصف: | Abstract. Background:. Diabetic nephropathy (DN) is a common microvascular complication of diabetes, which poses a serious threat to the health and life of patients. There is evidence that both α lipoic acid and olmesartan medoxomil have positive effects in the treatment of DN, but whether the 2 have synergistic effects and the effects on blood glucose and oxidation indicators are controversial. Methods:. This is a prospective parallel, randomized, double-blind, placebo-controlled trial to study the effects of α lipoic acid in combination with olmesartan medoxomil on blood glucose and oxidation indicators in patients with DN. Participants will be randomly assigned to a treatment group, which will receive α lipoic acid dispersive tablets combined with olmesartan medoxomil tablets, or a control group, which will receive olmesartan medoxomil tablets combined with placebo for 4 weeks, followed up for 12 weeks. Observation indicators include: glycemic indicators [fasting blood glucose, 2 hours postprandial blood glucose and glycosylated hemoglobin], the oxidation indicators [serum glutathione, superoxide dismutase, malondialdehyde, 8-hydroxydeox-yguanosine], and adverse reactions. Finally, SPASS 22.0 software will be used for statistical analysis of the data. Discussion:. This study will evaluate the effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with DN. The results of this study will provide a reference for the clinical use of α lipoic acid combined with olmesartan medoxomil in the treatment of DN. Trial registration:. OSF Registration number: DOI 10.17605/OSF.IO/VJWXS |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 0025-7974 1536-5964 00000000 |
| Relation: | http://journals.lww.com/10.1097/MD.0000000000029080; https://doaj.org/toc/0025-7974; https://doaj.org/toc/1536-5964 |
| DOI: | 10.1097/MD.0000000000029080 |
| URL الوصول: | https://doaj.org/article/de1cc604f6bf4ece9bd40a0daf39187c |
| رقم الأكسشن: | edsdoj.1cc604f6bf4ece9bd40a0daf39187c |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 00257974 15365964 00000000 |
|---|---|
| DOI: | 10.1097/MD.0000000000029080 |